

## Technology Advisory Committee C Interests Register

**Topic: Elafibranor for treating primary biliary cholangitis [ID6331]**

**Publication Date: 14/11/2024**

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Kate Ren	Committee Member	Direct Financial	Dr Kate Ren has provided statistical methodology consultancy service for Ipsen for elafibranor for treating primary biliary cholangitis.	03/09/2024	It was agreed that Kate's declaration would prevent her from participating in discussions on this appraisal.
Michael Chambers	Committee Member	Direct Financial	Michael Chambers has provided advice and attended an advisory board for Ipsen in cholangitis (elafibranor)	03/09/2024	It was agreed that Michael's declaration would prevent him from participating in discussions on this appraisal.
Professor David Jones	Clinical Expert	Direct Financial	<p>Professor Jones has research funding from Intercept, and undertaken consultancy or advisory board work for Intercept, Advanz, Ipsen, Umechrine and GSK. Professor Jones has also been sponsored as a speaker at educational meetings sponsored by Ipsen, GSK and Falk</p> <p>Professor Jones is also chair of the medical advisory board of the PBC</p>	03/09/2024	It was agreed that Professor Jones' declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
		Direct non-financial	Foundation, a national patients charity.		
Professor Palak Trivedi	Clinical Expert	Direct Financial	Professor Trivedi has received lecture fees, research grants and consultancy/advisory board fees from Ipsen, Advanz Pharma, GSK, Cymabay, Pliant Pharma, ChemoMab and Dr.Falk Pharma.	03/09/2024	It was agreed that Professor Jones' declaration would not prevent him from providing expert advice to the committee.